CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei,Koji Sasaki,Farhad Ravandi,Xuelin Huang,Hagop M Kantarjian,Jeffrey L Jorgensen,Partow Kebriaei,Joseph D Khoury,Jovitta Jacob,Issa F Khouri,Marina Konopleva,Rebecca Garris,Nitin Jain,Prithviraj Bose,Courtney D Dinardo,Tapan M Kadia,Meagan Rostykus,Rita Khouri,Bouthaina S Dabaja,Jan A Burger,Guillermo Montalban‐Bravo ,Philip A Thompson,Musa Yılmaz ,Lucia Masárová ,Paul Stolzmann ,Guillermo Garcia‐Manero ,Nicholas J Short,Sa A Wang ,Dan Nichols,Susan O’brien

doi:10.1182/blood-2020-143400

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, Koji Sasaki + Show 28 more

Open Access

https://doi.org/10.1182/blood-2020-143400

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 2

Affiliation: The University of Texas MD Anderson Cancer Center, University of California, Irvine Medical Center

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.